Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Evens, Andrew M."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study.
    Autorzy:
    Lee SF; Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.; Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hospital Authority, Hong Kong, China.
    Evens AM; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
    Ng AK; Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    Luque-Fernandez MA; Department of Non-Communicable Disease Epidemiology, Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK. .; Department of Non-Communicable Disease and Cancer Epidemiology, Instituto de Investigacion Biosanitaria de Granada (Ibs.GRANADA), University of Granada, Granada, Spain. .
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2021 Sep 09; Vol. 11 (1), pp. 17950. Date of Electronic Publication: 2021 Sep 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Registries*
    Social Class*
    Antineoplastic Agents, Immunological/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Healthcare Disparities/*economics
    Immunotherapy/*methods
    Lymphoma, Large B-Cell, Diffuse/*drug therapy
    Lymphoma, Large B-Cell, Diffuse/*mortality
    Rituximab/*therapeutic use
    Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Hong Kong/epidemiology ; Humans ; Lymphoma, Large B-Cell, Diffuse/epidemiology ; Male ; Middle Aged ; Survival Rate ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.
    Autorzy:
    Badar T; a Division of Hematology and Oncology , Medical College of Wisconsin , Milwaukee , WI , USA.
    Hamadani M; a Division of Hematology and Oncology , Medical College of Wisconsin , Milwaukee , WI , USA.
    Bachanova V; b Department of Medicine, Division of Hematology, Oncology and Transplantation , University of Minnesota , Minneapolis , MN , USA.
    Maddocks KJ; c Division of Hematology, Department of Internal Medicine , The James Cancer Hospital and Solove Research Institute at The Ohio State University , Columbus , OH , USA.
    Umyarova E; d Division of Hematology and Oncology , University of Vermont Cancer Center , Burlington , VT , USA.
    Chavez JC; e Division of Malignant Hematology , H. Lee Moffitt Cancer Center & Research Institute , Tampa , FL , USA.
    Epperla N; c Division of Hematology, Department of Internal Medicine , The James Cancer Hospital and Solove Research Institute at The Ohio State University , Columbus , OH , USA.
    Chhabra S; a Division of Hematology and Oncology , Medical College of Wisconsin , Milwaukee , WI , USA.
    Xavier AC; f Dept. of Pediatrics , University of Alabama , Birmingham , AL , USA.
    Karmali R; g Department of Internal Medicine , Rush University , Chicago , IL , USA.
    Salhab M; h Division of Hematology and Oncology , UMASS Memorial Medical Center , Worcestor , MA , USA.
    Reddy N; i Division of Hematology and Oncology , Vanderbilt University Medical Center , Nashville , TN , USA.
    Glenn MJ; j Department of Internal Medicine , Huntsman Cancer Institute, University of Utah , Salt Lake City , UT , USA.
    Hernandez-Ilizaliturri FJ; k Department of Medicine and Immunology , Roswell Park Cancer Institute , Buffalo , NY , USA.
    Flowers CR; l Department of Hematology and Medical Oncology , Winship Cancer Institute, Emory University , Atlanta , GA , USA.
    Evens AM; m Division of Hematology and Oncology , Tufts University School of Medicine and Cancer Center , Boston , MA , USA.
    Zhou Z; n Department of Hematology and Oncology , City of hope , Los angeles , CA , USA.
    Lansigan F; o Dartmouth-Hitchcock Medical Center , Lebanon , NH , USA.
    Barta SK; p Department of Hematology and Oncology , Fox Chase Cancer Center, Temple Health , Philadelphia , PA , USA.
    Cohen JB; l Department of Hematology and Medical Oncology , Winship Cancer Institute, Emory University , Atlanta , GA , USA.
    Fenske TS; a Division of Hematology and Oncology , Medical College of Wisconsin , Milwaukee , WI , USA.
    Costa LJ; q Department of Medicine , University of Alabama , Birmingham , AL , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2019 Apr; Vol. 60 (4), pp. 940-946. Date of Electronic Publication: 2018 Oct 02.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma, Large B-Cell, Diffuse/*drug therapy
    Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Combined Modality Therapy ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/etiology ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Salvage Therapy ; Treatment Failure ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
    Autorzy:
    Sharman JP; a Willamette Valley Cancer Institute and Research Center , US Oncology Research , Eugene , OR , USA.
    Forero-Torres A; b University of Alabama School of Medicine , Birmingham , AL , USA.
    Costa LJ; c Division of Hematology/Oncology , Medical University of South Carolina , Charleston , SC , USA.
    Flinn IW; d Sarah Cannon Research Institute , Nashville , TN , USA.
    Inhorn L; e Blue Ridge Cancer Care , Roanoke , VA , USA.
    Kelly K; f USC Norris Comprehensive Cancer Center , Los Angeles , CA , USA.
    Bessudo A; g California Cancer Associates for Research and Excellence , San Diego , CA , USA.
    Fayad LE; h Department of Lymphoma and Myeloma , M.D. Anderson Cancer Center, University of Texas , Houston , TX , USA.
    Kaminski MS; i Division of Hematology/Oncology , University of Michigan Comprehensive Cancer Center, Ann Arbor , MI , USA.
    Evens AM; j Rutgers Cancer Institute of New Jersey , New Brunswick , NJ , USA.
    Flowers CR; k Winship Cancer Institute , Atlanta , GA , USA.
    Sahin D; l F. Hoffmann-La Roche Ltd , Basel , Switzerland.
    Mundt KE; l F. Hoffmann-La Roche Ltd , Basel , Switzerland.
    Sandmann T; m Genentech Inc. , South San Francisco , CA , USA.
    Fingerle-Rowson G; l F. Hoffmann-La Roche Ltd , Basel , Switzerland.
    Vignal C; l F. Hoffmann-La Roche Ltd , Basel , Switzerland.
    Mobasher M; m Genentech Inc. , South San Francisco , CA , USA.
    Zelenetz AD; n Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center , New York , NY , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2019 Apr; Vol. 60 (4), pp. 894-903. Date of Electronic Publication: 2018 Oct 02.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*administration & dosage
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma, Large B-Cell, Diffuse/*drug therapy
    Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin/adverse effects ; Doxorubicin/therapeutic use ; Drug Interactions ; Drug Monitoring ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Neoplasm Staging ; Prednisone/adverse effects ; Prednisone/therapeutic use ; Prognosis ; Treatment Outcome ; Vincristine/adverse effects ; Vincristine/therapeutic use ; Young Adult
    SCR Protocol:
    CHOP protocol
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review.
    Autorzy:
    Fu J; a Division for Hematology/Oncology , Tufts Medical Center , Boston , MA , USA.; b Center for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS) , Tufts Medical Center , Boston , MA , USA.; c Tufts University School of Medicine , Boston , MA , USA.; d Tufts Medical Center Cancer Center of Stoneham , Stoneham , MA , USA.
    Upshaw J; c Tufts University School of Medicine , Boston , MA , USA.; e CardioVascular Center , Tufts Medical Center , Boston , MA , USA.
    Cohen J; c Tufts University School of Medicine , Boston , MA , USA.; f Center for the Evaluation of Value and Risk in Health (ICRHPS) , Tufts Medical Center , Boston , MA , USA.
    Rodday AM; b Center for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS) , Tufts Medical Center , Boston , MA , USA.; c Tufts University School of Medicine , Boston , MA , USA.
    Saunders T; b Center for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS) , Tufts Medical Center , Boston , MA , USA.
    Kelly M; c Tufts University School of Medicine , Boston , MA , USA.; g Division of Pediatric Hematology/Oncology , Floating Hospital for Children at Tufts Medical Center , Boston , MA , USA.
    Evens AM; a Division for Hematology/Oncology , Tufts Medical Center , Boston , MA , USA.; c Tufts University School of Medicine , Boston , MA , USA.
    Parsons SK; a Division for Hematology/Oncology , Tufts Medical Center , Boston , MA , USA.; b Center for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS) , Tufts Medical Center , Boston , MA , USA.; c Tufts University School of Medicine , Boston , MA , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Aug; Vol. 59 (8), pp. 1976-1980. Date of Electronic Publication: 2017 Dec 07.
    Typ publikacji:
    Letter; Systematic Review
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Heart Diseases/*diagnosis
    Hodgkin Disease/*drug therapy
    Hodgkin Disease/*therapy
    Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoradiotherapy/adverse effects ; Chemoradiotherapy/methods ; Heart Diseases/etiology ; Humans ; Risk Assessment ; Risk Factors ; Treatment Outcome
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies